Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (IMPALA-2)

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 48 weeks.

  • 1 views
  • 14 Jul, 2022
  • 50 locations
The Effect of Dupilumab on Lung Function and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma (VESTIGE)

high-resolution computed tomography (HRCT) scans, patient-reported outcomes, FeNO and spirometry. To evaluate safety of dupilumab

spirometry
leukotriene receptor antagonist
fractional exhaled nitric oxide
pulmonary function test
bronchodilator
  • 24 views
  • 09 Aug, 2022
  • 69 locations
The Effect of Dupilumab on Lung Function and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma (VESTIGE)

high-resolution computed tomography (HRCT) scans, patient-reported outcomes, FeNO and spirometry. To evaluate safety of dupilumab

  • 8 views
  • 29 Jul, 2022
  • 69 locations
Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema; A Multicenter, Prospective Trial (CONVERT)

This is a prospective, open-label, multi-center, single-arm study to be conducted at up to 20 investigational sites. The Study plans to enroll 140 subjects with severe emphysema and collateral ventilation in the target lobe. This protocol is designed to evaluate the utility of the AeriSeal System to occlude collateral air …

lung volume reduction
zephyr
aeriseal
  • 22 views
  • 23 Sep, 2022
  • 12 locations
Targeted Shortwave Diathermy Combined With Perceptual Training for Patients With Severe Traumatic Optic Neuropathy

subjects with severe TON after EOND surgery were randomly assigned to either a rehabilitation (Reh) group or nonrehabilitation (Nreh) group. Methods: High-resolution computed tomography and MRI were

  • 0 views
  • 11 Dec, 2021
  • 1 location
Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

following the initiation of therapy. Additional studies including pulmonary function studies, serum for bio markers, 6 minute walk distance and a high-resolution computed tomography (HRCT) scan (only at the

nintedanib
ct scan
idiopathic pulmonary fibrosis
dyspnea
pirfenidone
  • 4 views
  • 18 May, 2022
  • 1 location
Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis

Silicosis is one of the leading causes of occupational respiratory disease worldwide. It is due to inhalation of respirable crystalline silica and can lead to progressive massive fibrosis (PMF), respiratory failure, and death. It is estimated that it causes more than 10,000 deaths a year worldwide, mainly in developing countries, …

  • 0 views
  • 25 Mar, 2022
Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease (PULMORA)

Pulmonary abnormalities are present in up to 60% of patients with early rheumatoid arthritis (RA), and up to 10% of the patients will develop clinical interstitial lung disease (ILD). Recent data indicate that inhibition of Janus kinase is beneficial for this extra-articular manifestation. Our goal is to determine whether tofacitinib …

methotrexate
DMARD
tofacitinib
antirheumatics
prednisone
  • 1 views
  • 10 May, 2022
  • 1 location
Negative Pressure Ventilation-rehabilitation on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

This investigator-initiated, prospective, single center, randomized, controlled clinical trial enrolled patients with stable Global Initiative for Chronic Obstructive Lung Disease stage II-IV chronic obstruction pulmonary disease. The primary outcome was 2-year acute exacerbation rates.

  • 0 views
  • 18 Apr, 2021
  • 1 location
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 (ENDCOV-I)

This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of Nintedanib on slowing the rate of lung disease in patients who have been diagnosed with COVID-19, and have ongoing …

bronchiectasis
nintedanib
assisted ventilation
fibrosis
interstitial lung disease
  • 6 views
  • 05 May, 2022
  • 8 locations